Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes
Time: 9:00 am
day: Conference Day One AM
Details:
- Understand the rationale for targeting the SORT1 receptor in cancer
- Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform
- Discuss the unique multimodal MOA of this PDC
- Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinations
